Pfenex
Pfenex develops biosimilar therapeutics and novel vaccines for the treatment and prevention of critical human health issues.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
$438m Valuation: $438m 8.6x EV/Revenue | Acquisition | ||
| Total Funding | 000k | ||
| USD | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | (46 %) | 173 % | 24 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (89 %) | (260 %) | (37 %) | 69 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 102 % | - | - | - |
Source: Company filings or news article
Related Content
Pfenex Inc. is a biotechnology company specializing in the development of protein therapeutics aimed at transforming patient outcomes. Operating in the pharmaceutical and healthcare market, Pfenex focuses on creating and commercializing biosimilar and novel biologic drugs. The company serves a diverse range of clients, including healthcare providers, pharmaceutical companies, and patients in need of advanced therapeutic options. Pfenex's business model revolves around leveraging its proprietary protein expression technology to develop high-quality, cost-effective therapeutic proteins. The company generates revenue through the sale of its FDA-approved products, such as PF708 for osteoporosis, and through partnerships and licensing agreements for its pipeline candidates. Pfenex's commitment to innovation and patient care positions it as a key player in the biopharmaceutical industry.
Keywords: biotechnology, protein therapeutics, biosimilars, biologics, osteoporosis, FDA-approved, pharmaceutical, healthcare, innovation, patient outcomes.